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1. Introduction 
Sulfur Mustard (SM) is a potent toxic alkylating agent that has been used as a chemical 
warfare gas during the World War I and in the Iran-Iraq conflict between 1983 and 1988(1). 
SM can cause serious organ damages especially ocular, neurologic, cutaneous, bone 
marrow, and pulmonary complications (1). The previous studies have shown that the 
respiratory complications are the most common late complications of SM toxic exposure 
including chronic obstructive pulmonary disease (COPD), chronic bronchitis, bronchiolitis 
oblitrans, bronchiectasis, airway hyperresponsiveness, and lung fibrosis (2-6).The COPD 
which occur after SM exposure is known as "Mustard lung" (7 ). Since about 45000 patients 
are now suffering from long term complications of SM toxic exposure, the evaluation of its 
pathogenesis and finding the possible ways for treatment is necessary. During the last 
decade, especial attention to the possible underlying mechanism of COPD due to SM 
intoxications has been applied. Our previous studies have shown that in COPD patients due 
to SM exposure inflammatory markers (highly sensitive CRP, interleukin 6) are elevated and 
these markers have direct association with the severity of disease (8,9). The finding which 
recommends the role of systemic inflammation in the pathogenesis of COPD due to SM 
intoxication like the COPD due to other causes. In this chapter the historical points, probable 
pathogenesis, clinical manifestation, and diagnosis of mustard lung will be discussed. 
2. Historical background 
Mustard gas was possibly developed as early as 1822 by César-Mansuete Desperetez (1798–
1863) (10). SM was used as the late 1880 for treating minor tumors (11). Mustard gas is the 
most widely – used vesicant chemical war agent in the past century (2).Unfortunately SM 
was first employed effectively as a weapon in World War by the Germans on the British at 
Ypres (3, 11). It was then used during the Iran-Iraq war (1983-1988) and more than 100 000 
military and civilian people were injured by SM gas (12).Now, over 45000 patients are 
suffering from the late complications of SM exposure (11, 12) and now SM is included as a 
threat to both military and civilians (13). 
3. Sulfur mustard 
SM or [bis-(2-chloroethyl) sulfate] (Fig.1) is also known as" Yperite" (Ypres was the name of 
the place which it was first used), "Lost" (the initials of two German chemists), and "yellow 
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cross" (it was a symbol means "skin damaging agent" during world war I) (11,12) .It is a 
colorless to yellowish- brown oily liquid at room temperature that converts to a gas with 
weapon system delivery (3,11).It has the odor of mustard, garlic, or onion (3 ).  
 
Fig. 1. Molecular structure of sulfur mustard 
SM is absorbed by different ways: inhalation, through the skin, eyes, and gasterointestinal 
tract due to consumption of contaminated food (3 ).In large amount exposure, it can cause 
damages in rapid proliferating tissues particularly bone marrow (3 ).SM can cause different 
biochemical reactions and alterations in DNA structure ( 1). 
4. Classification 
Following the SM exposure, acute and late (long term) complications may occur. The long 
term complications of SM exposure are much serious than acute effects .Generally the long 
term effects of SM exposure occur several years after a mild contact and are totally different 
from continuous longtime exposure (mainly occupational exposure) (12, 13).Several studies 
in Iran demonstrated that the most common late complication are respiratory problems, 
including chronic obstructive pulmonary disease (COPD), chronic bronchitis, bronchiolitis 
obliterans, bronchiectasis, airway hyperreactivity, and lung fibrosis (3-6).Ophthalmologic 
and cutenous problems are also seen in this period. Unfortunately, the respiratory problems 
usually exacerbate over time (12).A unique form of COPD known as" Mustard lung" is 
frequently seen as a long term complication (7). 
5. Pathogenesis 
The exact mechanism of late pulmonary complication of SM exposure are not fully defined 
(14).Although the pathogenesis of COPD has completely determined and is mainly 
dependent on chronic inflammation and oxidative stress following activation of airway 
inflammatory cells, but there are few studies about the inflammatory basis of mustard lung 
(8,9,15).The pathological studies have shown that mustard lung is a neutrophilic / 
lymphocytic disorder (16,17).Also bronchiolar disease with varying degrees of inflammation 
as the main pathological finding, was demonstrated in a recent pathologic study in patients 
with sulfur mustard injury (18 ). According to the previous pathological studies, it seems 
that activation of inflammatory cells and generation of reactive oxygen species resulting in 
oxidative stress be involved (16, 17). It has been shown that decreased glutathione and 
increased serum malondialdehyde levels in mustard lung patients can be an indicator of 
oxidative-antioxidative system imbalance (16). The previous animal model studies have 
mentioned that the activation of inflammatory cells are involved in the pathogenesis of SM 
lung injury (19, 20).It is well documented that oxidative antioxidative imbalance may result 
in oxidative stress and triggering inflammatory process (21). 
Despite the accepted role of inflammatory cytokines in acute pulmonary complications of 
SM, there are limited studies on the level of cytokines in the long term complications of SM 
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injury .Our recent studies (8,9) on 50 stable mustard lung patients with all stages according 
to GOLD (Global Initiative for Chronic Obstructive Lung Disease) classification (Fig.2) 
(22),showed that  despite the exclusion of smoking, cardiovascular diseases, infections, and 
other important inflammatory conditions, serum level of highly sensitive c reactive protein 
(hs-CRP) and interleukin 6 (IL-6), as inflammatory markers, are elevated in mustard lung 
patients in comparison of normal controls and are directly related to severity of COPD 
according to spirometry findings (Fig.3,4)(8,9). It is clearly documented that IL-6 has an 
important part in reduced forced expiratory volume in one second (FEV1), impaired 
functional capacity, and worsening the underlying inflammatory condition by release of 
acute phase proteins (23,24).Also the previous studies in COPD patients have shown that 
the serum hs-CRP is related to severity of airflow obstruction (25,26). 
 
Fig. 2. The frequency of GOLD stages in mustard lung patients (9) 
 
Fig. 3. The correlation of FEV1 and hs-CRP in mustard lung patients (8) 
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Fig. 4. The correlation of FEV1 and IL-6 in mustard lung patients (9) 
Furthermore, the BODE (body mass index, obstruction, dyspnea, and exercise capacity) 
index, that is more reliable parameter of COPD morbidity and mortality, was significantly 
correlated with the serum IL-6 level (Fig 5) (9). 
 
Fig. 5. The correlation of BODE index and serum IL-6 (9) 
Additionally increased levels of IL-8 in the bronchoalveolar lavage fluid of patients with 
sulfur mustard poisoning and late pulmonary complications have been demonstrated (15) 
Despite these studies, few studies reported that inflammatory mediators probably do not 
have any major role in the pathogenesis and persistence of pulmonary complications of 
sulfur mustard exposure (27). 
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These findings provide evidence of the possibility of an inflammatory basis for the late 
pulmonary complications of sulfur mustard exposure and is in accordance with previous 
studies in other COPD patients which pointed out that, even during the stable phase of 
COPD, serum levels of inflammatory markers, including IL-6, may be raised (8,9)  
6. Clinical manifestations 
The most common compliant of mustard lung patients is chronic cough (12).A study 
showed that a triad of cough, expectoration and dyspnea was found in more than 80% of 
Iranian veterans 3 years after the exposure (1,28). 
On physical examination, crackles, wheezing, and rhonchi depending to the state of the 
patient, can be seen (12, 29).The attacks of COPD exacerbation with increasing the severity 
of dyspnea, cough, and discoloration of sputum, is a common clinical presentation (12, 30). 
The late pulmonary complications of SM injury may occur in patients who had not developed 
acute symptoms (12).A study on patients who did not have acute symptoms showed that 38% 
of these patients had air trapping on high resolution CT (HRCT) of chest (31). 
Our previous studies on exercise tolerance of mustard lung patients have shown that the 
mean exercise capacity of these patients measured by 6 minute walk distance test (6MWD) 
has been decreased in comparison of normal population (8,9 ).Also the evaluation of quality 
of life in mustard lung patients showed significant impairment in this assessment by saint 
George respiratory questionnaire (SGRQ) (8,9,32).Additionally ,in our study the BODE 
(body mass index, obstruction, dyspnea, and exercise capacity) index had significant 
correlation with the serum level of inflammatory markers (8,9). 
7. Diagnostic evaluation 
Pulmonary function tests 
Spirometry is a common diagnostic way for staging the severity of pulmonary impairment. 
Like to COPD due to other causes, generally an obstructive pattern is present in patients. A 
study showed that FEV1 is decreased at a rate of 50 ml/year in mustard lung patients (11, 33). 
In body plethysmography, total lung capacity (TLC) and residual volume (RV) are 
markedly increased and Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) 
remains normal (11, 34). 
Chest x-ray 
Since the majority of mustard lung patients have normal or near normal chest x-ray (CXR) , 
some authors believe that CXR is not a reliable diagnostic imaging modality in these 
patients (12,35). Increased bronchovascular markings, and hyperinflation, pulmonary 
hypertension can be seen in CXR (12, 36). 
HRCT 
Chest HRCT has became a imaging modality of choice in SM patients (12).Air trapping and 
airway abnormal wall thickening are the most common HRCT finding (12,37). 
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Unfortunately, there are no cure for mustard lung disease (11 ).Bronchodilators, inhaled 
steroids, long- term oxygen therapy, and pulmonary rehabilitation are different 
therapeutical strategies which are used in these patients (11 ).The combination of long – 
acting beta agonists (LABAs) and inhaled steroids has been shown to be effective (11,38,39 ). 
In mustard lung patients, systemic steroid is only recommended during exacerbations 
(11).The prolonged use of systemic steroids should be avoided because of severe 
complication (39). 
As we mentioned earlier, the oxidative – antioxidative imbalance may be an underlying 
mechanism in mustard lung patients. So the potent antioxidant agents are tried for this 
purpose. N-Acetylcysteine is an antioixidat and mucolytic drug that in  double- blind 
clinical trial, improved dyspnea, cough, and sputum  after 4 months of treatment (11,40). 
8. Conclusion 
SM can cause serious late pulmonary complications. A unique form of COPD, known as 
mustard lung, is frequently encountered in patients .Systemic inflammation may be 
involved in pathogenesis of mustard lung. Unfortunately there is no cure for these patients. 
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